SG10201913290QA - Combinations of lsd1 inhibitors for the treatment of hematological malignancies - Google Patents

Combinations of lsd1 inhibitors for the treatment of hematological malignancies

Info

Publication number
SG10201913290QA
SG10201913290QA SG10201913290QA SG10201913290QA SG10201913290QA SG 10201913290Q A SG10201913290Q A SG 10201913290QA SG 10201913290Q A SG10201913290Q A SG 10201913290QA SG 10201913290Q A SG10201913290Q A SG 10201913290QA SG 10201913290Q A SG10201913290Q A SG 10201913290QA
Authority
SG
Singapore
Prior art keywords
combinations
treatment
hematological malignancies
lsd1 inhibitors
lsd1
Prior art date
Application number
SG10201913290QA
Inventor
Filippo Ciceri
Serena Lunardi
Tamara Maes
Crusat Cristina Mascaro
Fernandez De La Cuesta Inigo Tirapu
Original Assignee
Oryzon Genomics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa filed Critical Oryzon Genomics Sa
Publication of SG10201913290QA publication Critical patent/SG10201913290QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG10201913290QA 2016-03-15 2017-03-13 Combinations of lsd1 inhibitors for the treatment of hematological malignancies SG10201913290QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16382117 2016-03-15

Publications (1)

Publication Number Publication Date
SG10201913290QA true SG10201913290QA (en) 2020-03-30

Family

ID=55752234

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913290QA SG10201913290QA (en) 2016-03-15 2017-03-13 Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SG11201807972YA SG11201807972YA (en) 2016-03-15 2017-03-13 Combinations of lsd1 inhibitors for the treatment of hematological malignancies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201807972YA SG11201807972YA (en) 2016-03-15 2017-03-13 Combinations of lsd1 inhibitors for the treatment of hematological malignancies

Country Status (15)

Country Link
US (3) US11013698B2 (en)
EP (1) EP3429570A1 (en)
JP (1) JP7082263B2 (en)
KR (2) KR102646126B1 (en)
CN (2) CN114377137A (en)
AR (1) AR108686A1 (en)
AU (2) AU2017233886B2 (en)
BR (1) BR112018068532A2 (en)
CA (1) CA3017408A1 (en)
IL (1) IL261717B2 (en)
MX (2) MX2018011100A (en)
MY (1) MY197785A (en)
RU (1) RU2766259C2 (en)
SG (2) SG10201913290QA (en)
WO (1) WO2017157813A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104203914B (en) 2011-10-20 2017-07-11 奥瑞泽恩基因组学股份有限公司 As (miscellaneous) aryl rings propanamine compounds of LSD1 inhibitor
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
MX2018011100A (en) 2016-03-15 2019-01-10 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies.
EA201892075A1 (en) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
SI3307267T1 (en) 2016-06-10 2019-08-30 Oryzon Genomics, S.A. Multiple sclerosis treatment
US11685782B2 (en) 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
KR20210006426A (en) * 2018-05-04 2021-01-18 오리존 지노믹스 에스.에이. Stable pharmaceutical preparation
AU2020296179A1 (en) * 2019-06-20 2022-02-03 Celgene Quanticel Research, Inc. Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
KR20210038366A (en) * 2019-09-30 2021-04-07 한미약품 주식회사 A pharmaceutical composition comprising FLT3 inhibitor and MDM2 inhibitor for the treatment of the acute myeloid leukemia
EP4319732A1 (en) * 2021-04-08 2024-02-14 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
CN113082211A (en) * 2021-04-14 2021-07-09 南方医科大学珠江医院 Pharmaceutical composition for treating NPM1 mutant acute myeloid leukemia and application thereof
WO2023063784A1 (en) * 2021-10-14 2023-04-20 (주)파로스아이바이오 Composition for combination therapy, comprising 2,3,5-substituted thiophene compound
GB202115017D0 (en) 2021-10-20 2021-12-01 Univ London Queen Mary Sequential treatments and biomarkers to reverse resistance to kinase inhibitors
WO2023067058A1 (en) 2021-10-20 2023-04-27 Queen Mary University Of London Sequential treatments and biomarkers to reverse resistance to kinase inhibitors

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2709712A (en) 1950-04-22 1955-05-31 Eastman Kodak Co Synthesis of vitamin a-active polyenes
DE1140941B (en) 1960-11-02 1962-12-13 Jiri Smrt Process for the preparation of 6-azacytidine
US3968249A (en) 1963-01-22 1976-07-06 E. R. Squibb & Sons, Inc. Method of treating malignant neoplastic disease
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
WO1994006802A1 (en) 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
JP3354090B2 (en) 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト Differentiation inducer
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
WO2004080421A2 (en) 2003-03-12 2004-09-23 Pharma Mar, S.A. Improved antitumoral treatments
NZ543897A (en) 2003-05-30 2009-04-30 Gemin X Pharmaceuticals Canada Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
US7741086B2 (en) 2004-12-16 2010-06-22 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
DE602005022826D1 (en) 2005-02-18 2010-09-23 Universitaetsklinikum Freiburg Control of androgen receptor-dependent gene expression by inhibition of amine oxidase activity of lysine-specific demethylase (LSD1)
ES2493466T3 (en) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Apoptosis promoters
AU2006279943B2 (en) 2005-08-10 2012-02-16 The Johns Hopkins University Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors
KR101549364B1 (en) 2006-03-17 2015-09-01 암비트 바이오사이언시즈 코포레이션 Imidazolothiazole compounds for the treatment of disease
US20110092601A1 (en) 2007-04-13 2011-04-21 The Johns Hopkins University Lysine-specific demethylase inhibitors
US8034779B2 (en) 2007-08-13 2011-10-11 Case Western Reserve University Inhibitors of BCL-2
CN101868446A (en) 2007-09-25 2010-10-20 托波塔吉特英国有限公司 The synthetic method of some hydroxamic acid compound
EP2317992A2 (en) 2008-07-24 2011-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Preventing or treating viral infection using an inhibitor of the lsd1 protein, a mao inhibitor or an inhibitor of lsd1 and a mao inhibitor
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
CA2755976C (en) 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
PE20120345A1 (en) 2009-05-26 2012-05-17 Abbvie Bahamas Ltd DERIVATIVES OF 2- (1H-PIRROLO [2,3-B] PYRIDIN-5-ILOXI) -N-FENYLSULFONYLBENZAMIDE AS INHIBITORS OF ANTI-APOPTOTIC PROTEINS
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
EP2258865A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Lysine-specific demethylase 1 (LSD1) is a biomarker for breast cancer
WO2010143582A1 (en) 2009-06-11 2010-12-16 公立大学法人名古屋市立大学 Phenylcyclopropylamine derivatives and lsd1 inhibitors
WO2011022489A2 (en) 2009-08-18 2011-02-24 The Johns Hopkins University (bis) urea and (bis) thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
NZ601655A (en) 2010-01-22 2014-10-31 Acetylon Pharmaceuticals Inc Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US20130197088A1 (en) 2010-03-12 2013-08-01 Robert A. Casero, JR. Compositions and Methods for Combinations of Oligoamines with 2-Difluoromethylornithine (DFMO)
CA2796726C (en) 2010-04-19 2021-02-16 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
PL2560949T3 (en) 2010-04-20 2017-01-31 Università Degli Studi Di Roma "La Sapienza" Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2
EP2569429A4 (en) 2010-05-14 2013-09-25 Dana Farber Cancer Inst Inc Compositions and methods for modulating metabolism
RS57331B1 (en) 2010-07-29 2018-08-31 Oryzon Genomics Sa Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
US20130303545A1 (en) 2010-09-30 2013-11-14 Tamara Maes Cyclopropylamine derivatives useful as lsd1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
MX2013006251A (en) 2010-12-03 2013-10-01 Epizyme Inc Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes.
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
US20140163041A1 (en) 2011-02-08 2014-06-12 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
CA2828212A1 (en) 2011-02-23 2012-08-30 Shiraz Mujtaba Inhibitors of bromodomains as modulators of gene expression
MX347913B (en) 2011-03-25 2017-05-17 Glaxosmithkline Intellectual Property (No 2) Ltd Cyclopropylamines as lsd1 inhibitors.
WO2012156537A2 (en) 2011-05-19 2012-11-22 Oryzon Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
EP2741741A2 (en) 2011-05-19 2014-06-18 Oryzon Genomics, S.A. Lysine demethylase inhibitors for inflammatory diseases or conditions
PL2732157T3 (en) 2011-07-14 2019-10-31 Esm Energie Und Schwingungstechnik Mitsch Gmbh Elastic, hydraulic or pneumatic pressure-accumulator bearing and the use thereof in wind power turbines
CN104203914B (en) 2011-10-20 2017-07-11 奥瑞泽恩基因组学股份有限公司 As (miscellaneous) aryl rings propanamine compounds of LSD1 inhibitor
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9763956B2 (en) 2012-06-19 2017-09-19 The Broad Institute, Inc. Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
KR101911048B1 (en) 2013-01-29 2018-10-24 삼성전자주식회사 Pharmaceutical composition for combination therapy containing p53 activator and c-Met inhibitor
JP2016510039A (en) 2013-02-28 2016-04-04 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ Method for treating human cytomegalovirus infection and disease with bromodomain inhibitors
US11446309B2 (en) * 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
MX2016009753A (en) 2014-01-28 2017-07-07 Buck Inst For Res On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders.
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
EP3307909A1 (en) 2015-06-12 2018-04-18 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
EP3359684A1 (en) 2015-10-09 2018-08-15 Oryzon Genomics, S.A. Gene expression biomarkers for personalized cancer care to epigenetic modifying agents
EA201892075A1 (en) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
MX2018011100A (en) 2016-03-15 2019-01-10 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies.
EP3430015A1 (en) 2016-03-16 2019-01-23 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
SI3307267T1 (en) 2016-06-10 2019-08-30 Oryzon Genomics, S.A. Multiple sclerosis treatment
WO2018083138A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
CN110996949A (en) 2017-08-03 2020-04-10 奥瑞泽恩基因组学股份有限公司 Methods for treating behavioral changes
KR20210006426A (en) 2018-05-04 2021-01-18 오리존 지노믹스 에스.에이. Stable pharmaceutical preparation
CA3130638A1 (en) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
CN113631164A (en) 2019-03-20 2021-11-09 奥莱松基因组股份有限公司 Methods of treating attention deficit hyperactivity disorder using KDM1A inhibitors such as the compound varespita
WO2020193631A1 (en) 2019-03-25 2020-10-01 Oryzon Genomics, S.A. Combinations of iadademstat for cancer therapy

Also Published As

Publication number Publication date
EP3429570A1 (en) 2019-01-23
AR108686A1 (en) 2018-09-19
KR102511028B1 (en) 2023-03-16
JP2019508439A (en) 2019-03-28
MX2018011100A (en) 2019-01-10
US20190083417A1 (en) 2019-03-21
US20170281566A1 (en) 2017-10-05
CN114377137A (en) 2022-04-22
MY197785A (en) 2023-07-13
RU2018136153A (en) 2020-04-15
CN109462980A (en) 2019-03-12
KR20230042755A (en) 2023-03-29
US20220331265A1 (en) 2022-10-20
US11013698B2 (en) 2021-05-25
RU2766259C2 (en) 2022-02-10
MX2022013612A (en) 2023-07-18
SG11201807972YA (en) 2018-10-30
CN109462980B (en) 2022-02-08
AU2017233886A1 (en) 2018-11-01
BR112018068532A2 (en) 2019-01-29
IL261717B (en) 2022-10-01
KR102646126B1 (en) 2024-03-11
AU2023200271A1 (en) 2023-02-16
WO2017157813A1 (en) 2017-09-21
AU2017233886B2 (en) 2022-10-20
CA3017408A1 (en) 2017-09-21
IL261717A (en) 2018-10-31
KR20180117710A (en) 2018-10-29
JP7082263B2 (en) 2022-06-08
RU2018136153A3 (en) 2020-06-30
IL261717B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
IL261717B (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
IL283267A (en) Inhibitors of the menin-mll interaction
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
IL259560A (en) Inhibitors of the menin-mll interaction
IL260217B (en) Lsd1 inhibitors
PL3512850T3 (en) Inhibitors of the menin-mll interaction
HK1251614A1 (en) Method for the treatment of malignancies
IL261721A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
PT3297628T (en) Calcineurin inhibitors of the setron family for the treatment of hearing loss
LT3377064T (en) Orvepitant for the treatment of chronic cough
HK1250343A1 (en) Calcineurin inhibitors of the setron family for the treatment of hearing loss